Endocrine Abstracts

Introduction: Ipilimumab is a monoclonal antibody directed against CTLA-4 used primarily in treatment of malignant melanoma. Immunological side effects are common, amongst others it may lead to hypophysitis. We studied clinical characteristics of IpiH and compared it to cases of primary hypophysitis (PH).Methods: We conducted a retrospective single centre study in 75 hypophysitis patients (60 primary, 15 Ipilimumab-induced in patients with melanoma). Gro...